Citius Pharmaceuticals 과거 순이익 실적

과거 기준 점검 0/6

Citius Pharmaceuticals 의 수입은 연평균 -12.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 12.6%의 비율로 증가했습니다. 매출은 연평균 109.2%의 비율로 증가해 왔습니다.

핵심 정보

-12.39%

순이익 성장률

12.49%

주당순이익(EPS) 성장률

Pharmaceuticals 산업 성장률	5.95%
매출 성장률	109.17%
자기자본이익률	-41.57%
순이익률	-909.87%
최근 순이익 업데이트	31 Dec 2025

최근 과거 실적 업데이트

업데이트 없음

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28

매출 및 비용 세부 내역

Citius Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqCM:CTXR 매출, 비용 및 순이익 (USD Millions)
날짜	매출	순이익	일반관리비	연구개발비
31 Dec 25	4	-36	31	9
30 Sep 25	0	-37	29	9
30 Jun 25	0	-41	31	10
31 Mar 25	0	-43	31	12
31 Dec 24	0	-41	31	11
30 Sep 24	0	-40	30	12
30 Jun 24	0	-40	29	12
31 Mar 24	0	-37	26	13
31 Dec 23	0	-39	25	14
30 Sep 23	0	-34	22	15
30 Jun 23	0	-31	18	16
31 Mar 23	0	-31	17	17
31 Dec 22	0	-28	16	16
30 Sep 22	0	-34	16	18
30 Jun 22	0	-31	15	16
31 Mar 22	0	-29	15	13
31 Dec 21	0	-26	13	12
30 Sep 21	0	-25	11	12
30 Jun 21	0	-24	11	11
31 Mar 21	0	-21	9	12
31 Dec 20	0	-21	9	12
30 Sep 20	0	-18	9	9
30 Jun 20	0	-17	8	9
31 Mar 20	0	-17	8	9
31 Dec 19	0	-16	7	9
30 Sep 19	0	-16	7	9
30 Jun 19	0	-15	7	8
31 Mar 19	0	-12	7	6
31 Dec 18	0	-13	6	8
30 Sep 18	0	-13	7	7
30 Jun 18	0	-13	7	5
31 Mar 18	0	-13	8	5
31 Dec 17	0	-11	8	2
30 Sep 17	0	-10	7	3
30 Jun 17	0	-10	7	4
31 Mar 17	0	-11	6	5
31 Dec 16	0	-9	5	4
30 Sep 16	0	-8	5	3
30 Jun 16	0	-7	3	2
31 Mar 16	0	-4	2	2
31 Dec 15	0	-3	1	2
30 Sep 15	0	-3	1	2
30 Jun 15	0	-3	2	1

양질의 수익: CTXR 은(는) 현재 수익성이 없습니다.

이익 마진 증가: CTXR는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: CTXR은 수익성이 없으며 지난 5년 동안 손실이 연평균 12.4% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 CTXR의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: CTXR은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(7.5%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: CTXR는 현재 수익성이 없으므로 자본 수익률이 음수(-41.57%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/03/13 13:50
종가	2026/03/13 00:00
수익	2025/12/31
연간 수익	2025/09/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서 생성에 사용된 분석 모델의 세부 정보는 저희 Github 페이지에서 확인하실 수 있으며, 보고서 사용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Citius Pharmaceuticals, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jason Kolbert	D. Boral Capital LLC.
Jason McCarthy	Maxim Group
Michael Okunewitch	Maxim Group

Citius Pharmaceuticals 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

Recent updates

Insufficient new directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Apr 06, 2026

New major risk - Financial position

Citius Pharmaceuticals, Inc. Provides Nasdaq Listing Compliance Update

Forecast breakeven date pushed back to 2027

New major risk - Share price stability

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.999749 million.

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.999749 million.

New major risk - Financial position

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.001962 million.

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $6.001962 million.

New major risk - Share price stability

Citius Pharmaceuticals, Inc. announced that it has received $1 million in funding

Forecast breakeven date moved forward to 2025

New major risk - Shareholder dilution

Citius Pharmaceuticals, Inc. announced a financing transaction

Consensus EPS estimates fall from profit to US$1.79 loss

Price target decreased by 85% to US$5.67

Consensus EPS estimates fall from profit to US$0.67 loss, revenue upgraded

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.999873 million.

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare & Medicaid Services

New major risk - Shareholder dilution

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 10, 2025

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3.000006 million.

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Forecast breakeven date moved forward to 2025

Price target decreased by 44% to US$54.00

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

Forecast breakeven date pushed back to 2026

New major risk - Share price stability

Nasdaq Hearings Panel Grants Citius Pharmaceuticals' Request to Continue its Listing on The Nasdaq Capital Market to Regain Compliance with the Bid Price Rule on or before December 3, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New major risk - Financial position

New minor risk - Profitability

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

New minor risk - Share price stability

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Price target decreased by 21% to US$3.17

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Consensus EPS estimates fall by 24%

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Forecast breakeven date pushed back to 2025

Price target increased by 25% to US$5.00

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Price target decreased to US$3.60